口腔给药系统市场、机会、成长动力、产业趋势分析与预测，2024-2032

在糖尿病和心血管疾病盛行率不断上升的推动下，2024年至2032年全球口腔给药系统市场规模将以8.6%的复合年增长率扩大。

口腔给药系统正在被设计为一种非侵入性的给药替代方案，确保改善吸收和更快起效。透过利用口腔黏膜进行药物输送，这些系统提高了患者的依从性和便利性，特别是对于那些需要频繁给药或难以口服片剂的患者。根据世界卫生组织的数据，心血管疾病 (CVD) 导致全球死亡，每年约 1,790 万人死亡。在这种背景下，口腔给药系统将自己定位为一种有效的解决方案，有望实现药物的快速吸收并提高患者对 CVD 管理的依从性。

市场分为产品类型、应用、系统类型、最终用途和区域。

就产品类型而言，到 2032 年，口腔给药系统产业的口腔凝胶细分市场将以相当大的复合年增长率成长。口腔凝胶专为透过口腔黏膜控制和持续释放药物而配製，旨在提高吸收和治疗效果。凝胶配方的持续进步是微调释放曲线和成分稳定性，进一步增强系统的功效。

从应用来看，神经系统疾病领域的口腔给药系统市场份额预计将在 2024 年至 2032 年期间上升。透过颊黏膜输送药物，这些系统可确保快速吸收并避免首过代谢，这是中枢神经系统药物的关键因素。这种方法不仅可以加强神经系统疾病的管理，还可以确保提高生物利用度和患者依从性。

从地区来看，由于患者对替代给药途径的偏好不断增加，预计欧洲口腔给药系统产业规模将在 2024 年至 2032 年间出现显着的复合年增长率。口腔给药可加快吸收并最大限度地减少胃肠道副作用，从而提高药物依从性。此外，区域进步的重点是开发更有效的配方和技术，以提高药物稳定性和释放曲线。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 对非侵入性给药方法的需求不断增加
    • 口腔给药技术的进步
    • 需要长期药物治疗的慢性病盛行率上升
    • 对口腔给药系统的认识与接受度不断提高
  • 产业陷阱与挑战
    • 由于患者不适，市场接受度有限
    • 开发和生产成本高
• 成长潜力分析
• 报销场景
• 未来市场趋势
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

• 主要趋势
• 口含片
• 颊膜
• 口腔凝胶
• 口腔喷雾剂
• 颊贴片

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 疼痛管理
• 荷尔蒙替代品
• 心血管疾病
• 神经系统疾病
• 呼吸系统疾病
• 成瘾治疗
• 心理健康障碍

第 7 章：市场估计与预测：按系统类型，2021 - 2032 年

• 主要趋势
• 矩阵系统
• 水库系统

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院
• 家庭护理设置
• 专科诊所
• 门诊手术中心
• 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• AbbVie Inc.
• Amgen Inc.
• Collegium Pharmaceutical, Inc.
• Endo International plc
• Galderma SA
• Indivior plc
• Johnson and Johnson Services, Inc.
• Kyowa Kirin Co., Ltd.
• Mallinckrodt plc
• Neurelis, Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceuticals Company Limited
• Teva Pharmaceutical Industries Ltd.

Global Buccal Drug Delivery Systems Market size will expand at an 8.6% CAGR from 2024 to 2032, fueled by the increasing prevalence of diabetes and cardiovascular diseases.

Buccal drug delivery systems are being crafted as a non-invasive alternative for medication administration, ensuring improved absorption and quicker action onset. By utilizing the mouth's mucous membranes for drug delivery, these systems boost patient compliance and convenience, especially for those needing frequent doses or struggling with oral tablets. As per WHO, cardiovascular diseases (CVDs) lead to global mortality, accounting for around 17.9 million deaths annually. In this context, buccal drug delivery systems are positioning themselves as a potent solution, promising swift medication absorption and heightened patient compliance for CVD management.

The market is segregated into product type, application, system type, end-use, and region.

In terms of product type, the buccal gels segment in the buccal drug delivery systems industry will grow at a considerable CAGR through 2032. This surge is driven by the rising demand for innovative medication administration methods. Formulated for controlled and sustained drug release via the buccal mucosa, buccal gels aim to boost absorption and therapeutic effectiveness. Ongoing advancements in gel formulations are fine-tuning release profiles and ingredient stability, further amplifying the efficacy of the systems.

By application, the buccal drug delivery systems market share from the neurological disorders segment is projected to rise from 2024 to 2032. This growth is attributed to the rising demand for specialized formulations and technologies. By delivering drugs via the buccal mucosa, these systems ensure rapid absorption and sidestep first-pass metabolism, a critical factor for central nervous system medications. Such an approach not only bolsters the management of neurological conditions but also guarantees improved bioavailability and patient adherence.

Regionally, the Europe buccal drug delivery systems industry size is projected to witness a significant CAGR between 2024 and 2032 due to the growing patient preference for alternative routes of administration. Buccal drug delivery enhances medication adherence by providing faster absorption and minimizing gastrointestinal side effects. Furthermore, regional advancements are focused on crafting more potent formulations and technologies to elevate drug stability and release profiles.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for non-invasive drug delivery methods
    • 3.2.1.2 Advancements in buccal drug delivery technologies
    • 3.2.1.3 Rising prevalence of chronic diseases requiring long-term medication
    • 3.2.1.4 Growing awareness and acceptance of buccal drug delivery systems
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited market acceptance due to patient discomfort
    • 3.2.2.2 High development and production costs
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Future market trends
• 3.6 Regulatory landscape
• 3.7 Technological landscape
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Buccal tablets
• 5.3 Buccal films
• 5.4 Buccal gels
• 5.5 Buccal sprays
• 5.6 Buccal patches

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
• 6.3 Hormone replacement
• 6.4 Cardiovascular diseases
• 6.5 Neurological disorders
• 6.6 Respiratory disorders
• 6.7 Addiction treatment
• 6.8 Mental health disorders

Chapter 7 Market Estimates and Forecast, By System Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Matrix systems
• 7.3 Reservoir systems

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Homecare settings
• 8.4 Specialty clinics
• 8.5 Ambulatory surgical centers
• 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 Collegium Pharmaceutical, Inc.
• 10.4 Endo International plc
• 10.5 Galderma SA
• 10.6 Indivior plc
• 10.7 Johnson and Johnson Services, Inc.
• 10.8 Kyowa Kirin Co., Ltd.
• 10.9 Mallinckrodt plc
• 10.10 Neurelis, Inc.
• 10.11 Novartis AG
• 10.12 Pfizer Inc.
• 10.13 Sanofi
• 10.14 Takeda Pharmaceuticals Company Limited
• 10.15 Teva Pharmaceutical Industries Ltd.